SG11201908580XA - Npra agonists, compositions, and uses thereof - Google Patents

Npra agonists, compositions, and uses thereof

Info

Publication number
SG11201908580XA
SG11201908580XA SG11201908580XA SG11201908580XA SG 11201908580X A SG11201908580X A SG 11201908580XA SG 11201908580X A SG11201908580X A SG 11201908580XA SG 11201908580X A SG11201908580X A SG 11201908580XA
Authority
SG
Singapore
Prior art keywords
international
suite
fatty acyl
pharmain
natriuretic peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Gerardo Castillo
Akiko Nishimoto-Ashfield
Elijah Bolotin
Original Assignee
Pharmain Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp filed Critical Pharmain Corp
Publication of SG11201908580XA publication Critical patent/SG11201908580XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
SG11201908580X 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof SG11201908580XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475147P 2017-03-22 2017-03-22
PCT/US2018/023491 WO2018175534A1 (en) 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
SG11201908580XA true SG11201908580XA (en) 2019-10-30

Family

ID=63585777

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908580X SG11201908580XA (en) 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof

Country Status (14)

Country Link
US (1) US20200017567A1 (ru)
EP (1) EP3601314A4 (ru)
JP (2) JP7126270B2 (ru)
KR (1) KR20190133201A (ru)
CN (1) CN110603260B (ru)
AU (1) AU2018239352A1 (ru)
BR (1) BR112019019720A2 (ru)
CA (1) CA3056433A1 (ru)
EA (1) EA201992226A1 (ru)
IL (1) IL269388A (ru)
MX (1) MX2019010960A (ru)
PH (1) PH12019550163A1 (ru)
SG (1) SG11201908580XA (ru)
WO (1) WO2018175534A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236690A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
EP3972590A4 (en) * 2019-05-22 2023-06-14 Merck Sharp & Dohme LLC NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
KR20230024353A (ko) * 2020-06-12 2023-02-20 파마인 코포레이션 C형 나트륨이뇨 펩타이드 및 이의 암 치료에서의 방법
CN115803338A (zh) * 2020-06-12 2023-03-14 药明公司 C型利尿钠肽及其治疗急性肺损伤的方法
US20240174727A1 (en) 2022-10-21 2024-05-30 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985722A (en) * 1973-12-12 1976-10-12 Ajinomoto Co., Inc. Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins
FR2687156B1 (fr) * 1992-02-12 1994-04-01 Roussel Uclaf Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
CN1062311C (zh) * 1996-12-27 2001-02-21 中国医学科学院基础医学研究所 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
SG159387A1 (en) * 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
JP2010530222A (ja) * 2007-06-06 2010-09-09 べーリンガー インゲルハイム インターナショナル ゲーエムベーハー ナトリウム利尿融合タンパク質
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
BRPI0904622A2 (pt) * 2008-05-23 2016-06-21 Asubio Pharma Co Ltd peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
SG192744A1 (en) * 2011-02-23 2013-09-30 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
US20120220528A1 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides

Also Published As

Publication number Publication date
IL269388A (en) 2019-11-28
EP3601314A4 (en) 2021-01-13
KR20190133201A (ko) 2019-12-02
JP2022090049A (ja) 2022-06-16
MX2019010960A (es) 2020-01-20
JP7126270B2 (ja) 2022-08-26
PH12019550163A1 (en) 2020-06-08
EA201992226A1 (ru) 2020-02-12
AU2018239352A1 (en) 2019-10-10
BR112019019720A2 (pt) 2020-04-28
JP2020511494A (ja) 2020-04-16
US20200017567A1 (en) 2020-01-16
CA3056433A1 (en) 2018-09-27
EP3601314A1 (en) 2020-02-05
WO2018175534A1 (en) 2018-09-27
CN110603260B (zh) 2023-11-07
CN110603260A (zh) 2019-12-20

Similar Documents

Publication Publication Date Title
SG11201908580XA (en) Npra agonists, compositions, and uses thereof
SG11201807472TA (en) Amanitin conjugates
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201901066UA (en) Novel alkaline stable immunoglobulin-binding proteins
SG11201906264YA (en) Improved serum albumin binders
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201906341XA (en) Improved serum albumin binders
SG11201908569QA (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
SG11201809064QA (en) Chimeric neurotoxins
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201811737SA (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407600UA (en) Novel process for preparation of antibody conjugates and novel antibody conjugates
SG11201909470TA (en) Bi- or multi-differentiated organoid
SG11201408173WA (en) Pyrimidinyl tyrosine kinase inhibitors
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201906728TA (en) Multimeric oligonucleotides having decreased kidney clearance
SG11201910206QA (en) Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201901673SA (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201811291QA (en) Industrial process for the preparation of cariprazine